New cream could fight HPV lesions in HIV patients
NCT ID NCT06233331
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a topical ointment called ACU-D1 for HPV-related vulvar and perianal lesions in people with HIV. Nine participants will apply the cream twice daily for 4 weeks. The main goal is to find the safest dose and see if the treatment can boost immune markers against HPV.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ACU-D1 ointment (proteasome inhibitor)
- What this could lead to
- If successful, this could point toward a topical treatment for HPV-related lesions in people with HIV, potentially reducing the need for surgery.
- What could go wrong
- This is a very early Phase 1 trial with only 9 participants, so it is primarily testing safety and dosing. It may not show clear effectiveness, and side effects are unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANAL INTRAEPITHELIAL NEOPLASIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Grady Memorial Hospital
Atlanta, Georgia, 30303, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can the HPV vaccine fully protect transgender women and people with HIV?
- Walking groups could shield HIV-Positive latino men from heart disease
- Friends helping friends: a novel social-network strategy to boost HIV prevention
- Tweets that tell a story: a new approach to boosting HPV vaccination
- Decade-Long study aims to unlock liver disease risks in HIV-Hepatitis b patients
- Could HPV shots start earlier? study tests vaccine in kids as young as 4